Upload
mandy
View
33
Download
0
Embed Size (px)
DESCRIPTION
New and ongoing areas of research. In the EuroQol Group. New research. International 5L valuation Discussed already EQ-5D-Y Youth version Disease specific adaptations ‘Bolt on’ additional dimensions. EQ-5D-Y: Youth. EQ-5D-Y: Youth. Translations Available in more than 20 languages - PowerPoint PPT Presentation
Citation preview
New and ongoing areas of research
In the EuroQol Group
New research• International 5L valuation
– Discussed already• EQ-5D-Y
– Youth version• Disease specific adaptations
– ‘Bolt on’ additional dimensions
EQ-5D-Y: Youth
EQ-5D-Y: Youth• Translations
– Available in more than 20 languages
– Youth between 7-12 years• Proxy versions
– In development
Administration seems OK
But not yet a value set• How should value the health states
– Children?– Parents?– The general public?
• How do you include:– Development backlog?– The remarkable coping skills children?
Are values different• Do we value health states different?
– For ourselves– For someone other like ourselves– For a 10-year child
• New paper of the 2012 Meeting
Values for children 10% lower
Feedback from the 2012 meeting
• Small number of health states• Still VAS
– Does this also apply for TTO?– Complication:
• How to apply TTO for health states of children?
• Descriptive system EQ-5d-Y is different!
Bolt-on• Do we miss dimensions?• In the past: EQ-6D
– Mobility; – Daily activity and self care;– Work performance– Family and leisure performance– Pain/discomfort– Present mood
• First attempts– EQ-5D+cog: addition of cognition?
EQ-5D+cog• Used in DALY WHO project
– Cognition was recognized as important• Lot of discussion
– Is it necessary?– Who is making the value set?– An unofficial set exist
• Based on mapping DALY project
• Is used…– But gives confusion
• No official status
Why not other dimensions?
• Developed already– Psoriasis– Vision
VF-14 by Visual acuity in macular degeneration
2423374311N =
Better-seeing Eye VA (distant, LogMAR)
lo thru 0.30
0.31 thru 0.60
0.61 thru 1.30
1.31 thru 2.00
2.01 thru hi
VF
-14
Inde
x
120
100
80
60
40
20
0
-20
114
EQ-5D by Visual acuity in macular degeneration
2423374311N =
Better-seeing Eye VA (distant, LogMAR)
lo thru 0.30
0.31 thru 0.60
0.61 thru 1.30
1.31 thru 2.00
2.01 thru hi
EQ-5
D1.2
1.0
.8
.6
.4
.2
0.0
-.2
71
102
147
91120
202
107101124
132
Evidence on EQ-5D: some examples
Hearing
SchizophreniaBipolar disorderVision
Depression and anxietySome cancersSkinPersonality disorder
Psoriasis
Estimation of utilities
• Used standard EQ-5D-3L TTO protocol• General public interviews in UK only
– N = 300• Sub-set of 49 states were included
using orthogonal design
Results
• OLS and random effects models estimated– Interaction terms; collapsing levels
• Both dimensions have a significant impact
• Some inconsistencies in the data• The largest gap is between level 3 and 4
(moderate and severe)
Modeling TTO values Psoriasis
Discussion 2012 meeting• No real problem when seen as pilot
– Convenience sample– TTO not standardised
• Methodological complications– Things get complicated for responders fast
• 223451 versus 122345• Cognition overload
– 57 = 78.125 health states• Similar values for 4th and 5th levels• Modeling stressed to the limit?